Drug Trial Radar · NCT05253651
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
325
Actual
Start
Oct 24, 2022
Primary completion
Dec 31, 2027
Study completion Jul 3, 2030
Sponsor
- Lead sponsor
- Seagen, a wholly owned subsidiary of PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Feb 24, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants in this study have colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresectable). Participants will be assigned randomly to the tucatinib group or standard of care group. The tucatinib group will get tucatinib, trastuzumab, and mFOLFOX6. The standard of care group will get either: * mFOLFOX6 alone, * mFOLFOX6 with bevacizumab, or * mFOLFOX6 with cetuximab mFOLFOX6 is a combination of multiple drugs. All of the drugs given in this study are used to treat this type of cancer.
Conditions
- Colorectal Neoplasms
Interventions
tucatinibDrug
300mg given by mouth (orally) twice daily
trastuzumabDrug
8mg/kg loading dose will be given into the vein (IV; intravenously) on Cycle 1 day 1, followed by 6mg/kg given by IV every 3 weeks thereafter.
bevacizumabDrug
5mg/kg given by IV every 2 weeks
cetuximabDrug
400mg/m2 loading dose will be given by IV on Cycle 1 day 1, followed by 250mg/m2 given by IV weekly
oxaliplatinDrug
85mg/m2 given by IV every 2 weeks. Component of mFOLFOX6.
leucovorinDrug
400mg/ m2 given by IV every 2 weeks. Component of mFOLFOX6.
levoleucovorinDrug
200mg/ m2 given by IV every 2 weeks. May be given in place of leucovorin. Component of mFOLFOX6.
fluorouracilDrug
400mg/m2 given by IV bolus then 2400mg/m2 given by continuous IV infusion (over 46-48 hours) every 2 weeks. Component of mFOLFOX6.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) by Blinded Independent Central Review (BICR)Time frame: Up to approximately 3 years
Locations
319 sites in 24 countries. Site status is shown where the registry gives one.
Palo Verde Hematology Oncology
Glendale, Arizona
Mayo Clinic Building - Phoenix
Phoenix, Arizona
Mayo Clinic Hospital
Phoenix, Arizona
Mayo Clinic
Scottsdale, Arizona
Los Angeles Cancer Network - Anaheim
Anaheim, California
Kaiser Permanente Anaheim Kraemer Medical Offices
Anaheim, California
Kaiser Permanente Baldwin Park Medical Center
Baldwin Park, California
Kaiser Permanente Bellflower Medical Offices
Bellflower, California
Kaiser Permanente Fontana Medical Center
Fontana, California
Los Angeles Cancer Network - Fountain Vally
Fountain Valley, California
Los Angeles Cancer Network - Corporate Office
Glendale, California
Los Angeles Hematology Oncology Medical Group
Glendale, California
Los Angeles Hematology Oncology Medical Group
Glendale, California
Kaiser Permanente South Bay Medical center
Harbor City, California
Kaiser Permanente Alton/Sand Canyon Medical Offices
Irvine, California
Los Angeles Hematology Oncology Medical Group
Los Angeles, California
USC Norris Koreatown - Medical Oncology
Los Angeles, California
Kaiser Permanente Los Angeles Medical Offices
Los Angeles, California
Keck Hospital of USC
Los Angeles, California
Los Angeles General Medical Center
Los Angeles, California
USC/Norris Comprehensive Cancer Center
Los Angeles, California
Kaiser Permanente West Los Angeles Medical Center
Los Angeles, California
USC Norris Oncology/Hematology - Newport Beach
Newport Beach, California
Kaiser Permanente Ontario Medical Center
Ontario, California
Kaiser Permanente Panorama City Medical Center
Panorama City, California
Keck Medical Center of USC Pasadena
Pasadena, California
Los Angeles Hematology Oncology Medical Group
Pasadena, California
Kaiser Permanente Riverside Medical Center
Riverside, California
Kaiser Permanente San Diego Mission Road (Regulatory and Lab Supplies)
San Diego, California
Kaiser Permanente Zion Medical Center
San Diego, California
Kaiser Permanente San Marcos Medical Offices
San Marcos, California
Los Angeles Hematology Oncology Medical Group
Van Nuys, California
Kaiser Permanente Woodland Hills Medical Center
Woodland Hills, California
Rocky Mountain Cancer Centers, LLP
Aurora, Colorado
Rocky Mountain Cancer Centers, LLP
Boulder, Colorado
Rocky Mountain Cancer Centers, LLP
Colorado Springs, Colorado
Rocky Mountain Cancer Centers, LLP
Denver, Colorado
Rocky Mountain Cancer Centers, LLP
Denver, Colorado
Rocky Mountain Cancer Centers, LLP
Lakewood, Colorado
Rocky Mountain Cancer Centers, LLP
Littleton, Colorado
Showing 40 of 319 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.